| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548904 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(4 years from now) | |
| US10537584 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(4 years from now) | |
| US8580293 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Jan, 2030
(5 years from now) | |
Milprosa is owned by Ferring Pharms Inc.
Milprosa contains Progesterone.
Milprosa has a total of 3 drug patents out of which 0 drug patents have expired.
Milprosa was authorised for market use on 29 April, 2020.
Milprosa is available in system;vaginal dosage forms.
Milprosa can be used as method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women.
The generics of Milprosa are possible to be released after 21 January, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2023 |
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM;VAGINAL
MILPROSA family patents
